XML 32 R14.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Note 5 - Transactions With Affiliated Companies | 12 Months Ended
--- | ---
Dec. 31, 2024
Notes to Financial Statements |
Investments in and Advances to Affiliates, Schedule of Investments [Text Block] | Note 5. Transactions with affiliated companies A non-controlled affiliated company is generally a portfolio company in which the Company owns 5% or more of such portfolio company’s voting securities but not more than 25% of such portfolio company’s voting securities. Transactions related to investments in non-controlled affiliated companies for the year ended December 31, 2024 were as follows:
|  |  |  |  |  |  |  |  |  | Year ended December 31, 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Fair value at |  |  |  |  |  |  |  |  |  |  | Transfers |  |  |  |  |  |  | Net |  |  |  |  |  |  | Fair value at |  |  |  |  |
Portfolio |  | December 31, |  |  |  |  |  |  | Principal |  |  | in/(out) at |  |  | Discount |  |  | unrealized |  |  | Net realized |  |  | December 31, |  |  | Interest |
Company |  | 2023 |  |  | Purchases |  |  | payments |  |  | fair value |  |  | accretion |  |  | gain/(loss) |  |  | gain/(loss) |  |  | 2024 |  |  | income |
|  | (In thousands) |
Aulea Medical, Inc. |  | $ | — |  |  | $ | 3 |  |  | $ | (40 | ) |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 37 |  |  | $ | — |  |  | $ | — |
Evelo Biosciences, Inc. |  |  | 1,132 |  |  |  | 244 |  |  |  | (1,430 | ) |  |  | — |  |  |  | — |  |  |  | 8,361 |  |  |  | — |  |  |  | 8,307 |  |  |  | — |
Total non-controlled affiliates |  | $ | 1,132 |  |  | $ | 247 |  |  | $ | (1,470 | ) |  | $ | — |  |  | $ | — |  |  | $ | 8,361 |  |  | $ | 37 |  |  | $ | 8,307 |  |  | $ | — |
Transactions related to investments in non-controlled affiliated companies for the year ended December 31, 2023 were as follows:
|  |  |  |  |  |  |  |  |  | Year ended December 31, 2023 |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Fair value at |  |  |  |  |  |  |  |  |  |  | Transfers |  |  |  |  |  |  | Net |  |  |  |  |  |  | Fair value at |  |  |  |  |
Portfolio |  | December 31, |  |  |  |  |  |  | Principal |  |  | in/(out) at |  |  | Discount |  |  | unrealized |  |  | Net realized |  |  | December 31, |  |  | Interest |
Company |  | 2022 |  |  | Purchases |  |  | payments |  |  | fair value |  |  | accretion |  |  | gain/(loss) |  |  | gain/(loss) |  |  | 2023 |  |  | income |
|  | (In thousands) |
Aulea Medical, Inc. |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Cadrenal Therapeutics, Inc. (1) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (906 | ) |  |  | — |  |  |  | 906 |  |  |  | — |  |  |  | — |  |  |  | — |
Evelo Biosciences, Inc. |  |  | — |  |  |  | 11 |  |  |  | (11,000 | ) |  |  | 39,505 |  |  |  | 35 |  |  |  | (27,419 | ) |  |  | — |  |  |  | 1,132 |  |  |  | 1,245 |
Total non-controlled affiliates |  | $ | — |  |  | $ | 11 |  |  | $ | (11,000 | ) |  | $ | 38,599 |  |  | $ | 35 |  |  | $ | (26,513 | ) |  | $ | — |  |  | $ | 1,132 |  |  | $ | 1,245 |
(1) As of December 31, 2023, the Company no longer owns 5% of more of the portfolio company. A controlled affiliated company is generally a portfolio company in which the Company owns more than 25% of such portfolio company’s voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). Transactions related to investments in controlled affiliated companies for the year ended December 31, 2024 were as follows:
|  |  |  |  |  |  |  |  |  | Year ended December 31, 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Fair value at |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Transfers |  |  |  |  |  |  | Net |  |  |  |  |  |  | Fair value at |  |  |  |  |
Portfolio |  | December 31, |  |  |  |  |  |  | Principal |  |  |  |  |  |  | in/(out) at |  |  | Discount |  |  | unrealized |  |  | Net realized |  |  | December 31, |  |  | Interest |
Company |  | 2023 |  |  | Purchases |  |  | payments |  |  | PIK |  |  | fair value |  |  | accretion |  |  | gain/(loss) |  |  | gain/(loss) |  |  | 2024 |  |  | income |
|  | (In thousands) |
Better Place Forests Co. |  | $ | 7,993 |  |  | $ | 3,750 |  |  | $ | — |  |  | $ | 805 |  |  | $ | — |  |  | $ | 14 |  |  | $ | (12,562 | ) |  | $ | — |  |  | $ | — |  |  | $ | 846 |
HIMV LLC |  |  | 6,230 |  |  |  | 227 |  |  |  | (592 | ) |  |  | — |  |  |  | 463 |  |  |  | — |  |  |  | (98 | ) |  |  | — |  |  |  | 6,230 |  |  |  | — |
Nexii, Inc. |  |  | — |  |  |  | 790 |  |  |  | — |  |  |  | — |  |  |  | 6,716 |  |  |  | — |  |  |  | 1,041 |  |  |  | — |  |  |  | 8,547 |  |  |  | 35 |
Swift Health Systems, Inc. |  |  | — |  |  |  | 1,887 |  |  |  | — |  |  |  | 826 |  |  |  | 15,462 |  |  |  | 2 |  |  |  | (1,135 | ) |  |  | — |  |  |  | 17,042 |  |  |  | 868 |
Total controlled affiliates |  | $ | 14,223 |  |  | $ | 6,654 |  |  | $ | (592 | ) |  | $ | 1,631 |  |  | $ | 22,641 |  |  | $ | 16 |  |  | $ | (12,754 | ) |  | $ | — |  |  | $ | 31,819 |  |  | $ | 1,749 |
Transactions related to investments in controlled affiliated companies for the year ended December 31, 2023 were as follows:
|  |  |  |  |  |  |  |  |  | Year ended December 31, 2023 |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Fair value at |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Transfers |  |  |  |  |  |  | Net |  |  |  |  |  |  | Fair value at |  |  |  |  |
Portfolio |  | December 31, |  |  |  |  |  |  | Principal |  |  |  |  |  |  | in/(out) at |  |  | Discount |  |  | unrealized |  |  | Net realized |  |  | December 31, |  |  | Interest |
Company |  | 2022 |  |  | Purchases |  |  | payments |  |  | PIK |  |  | fair value |  |  | accretion |  |  | gain/(loss) |  |  | gain/(loss) |  |  | 2023 |  |  | income |
|  | (In thousands) |
Better Place Forests Co. |  | $ | — |  |  | $ | 1,311 |  |  | $ | — |  |  | $ | 320 |  |  | $ | 4,580 |  |  | $ | 6 |  |  | $ | 1,776 |  |  | $ | — |  |  | $ | 7,993 |  |  | $ | 337 |
HIMV LLC |  |  | — |  |  |  | 146 |  |  |  | (516 | ) |  |  | — |  |  |  | 6,154 |  |  |  | — |  |  |  | 446 |  |  |  | — |  |  |  | 6,230 |  |  |  | — |
Total controlled affiliates |  | $ | — |  |  | $ | 1,457 |  |  | $ | (516 | ) |  | $ | 320 |  |  | $ | 10,734 |  |  | $ | 6 |  |  | $ | 2,222 |  |  | $ | — |  |  | $ | 14,223 |  |  | $ | 337 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the information summarizing investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates. It reflects specified information about ownership, financial results from, and financial position in such entities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details
Name: | us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration